Biotech deal activity in South Korea highlighted renewed momentum across platforms and oncology assets. Alteogen signed a potential $579 million license deal with Biogen, while Celltrion boosted its pipeline through a $137.45 million agreement with Kobiolabs. Other collaborations included SK Chemicals expanding work with J2H Biotech and Yatiri Bio entering a global option agreement with Oscotec. Taken together, the deals show continuing partner interest in therapeutic pipelines and enabling technologies coming out of South Korea. For global pharma partners, Korea remains a steady source of IP-rich early programs and later-stage candidates that can fit larger development portfolios.